XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.2

Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2021

Segment Reporting [Abstract]

Sales of Company's products

Sales of the Company’s products were as follows:

			Three Months Ended June 30,																																				Six Months Ended June 30,
			2021																		2020																		2021																		2020
($ in millions)			U.S.						Int’l						Total						U.S.						Int’l						Total						U.S.						Int’l						Total						U.S.						Int’l						Total
Pharmaceutical:
Oncology
Keytruda			$	2,347					$	1,829					$	4,176					$	2,043					$	1,345					$	3,388					$	4,528					$	3,548					$	8,076					$	3,949					$	2,722					$	6,672
Alliance revenue - Lynparza (1)			124						124						248						105						73						178						242						233						475						190						133						323
Alliance revenue - Lenvima (1)			88						93						181						98						53						151						173						137						310						188						91						279
Vaccines
Gardasil/Gardasil 9			454						781						1,234						168						488						656						766						1,385						2,151						629						1,124						1,753
ProQuad/M-M-R II/Varivax			386						130						516						263						115						378						718						246						965						596						217						813
RotaTeq			111						97						208						100						68						168						229						137						366						241						150						391
Pneumovax 23			100						52						152						21						96						117						173						150						323						203						170						373
Vaqta			22						34						56						17						11						28						47						43						90						47						41						88
Hospital Acute Care
Bridion			197						190						387						107						117						224						364						363						727						250						274						524
Prevymis			37						56						93						28						35						63						72						103						174						55						68						123
Noxafil			14						52						66						6						67						73						29						104						133						14						154						168
Primaxin			—						60						60						1						63						64						—						125						125						1						114						115
Cancidas			1						53						54						(2)						45						43						3						108						111						1						98						98
Invanz			(4)						52						48						—						43						43						—						104						104						6						102						108
Zerbaxa			(2)						1						(1)						17						15						32						(4)						(5)						(9)						37						32						69
Immunology
Simponi			—						202						202						—						191						191						—						416						416						—						406						406
Remicade			—						75						75						—						73						73						—						160						160						—						160						160
Neuroscience
Belsomra			14						63						78						22						61						84						32						125						157						49						114						163
Virology
Isentress/Isentress HD			74						118						192						76						120						196						145						256						401						151						290						441
Cardiovascular
Alliance revenue-Adempas/Verquvo (2)			81						(7)						74						73						6						79						149						—						149						122						11						133
Adempas			—						74						74						—						57						57						—						129						129						—						113						113
Diabetes
Januvia			284						500						784						413						441						854						632						961						1,593						768						860						1,628
Janumet			74						403						477						143						348						490						158						805						962						256						737						993
Other pharmaceutical (3)			245						301						546						259						289						548						485						644						1,130						513						637						1,149
Total Pharmaceutical segment sales			4,647						5,333						9,980						3,958						4,220						8,178						8,941						10,277						19,218						8,266						8,818						17,083
Animal Health:
Livestock			161						659						821						122						526						648						318						1,322						1,640						284						1,102						1,386
Companion Animals			298						353						651						220						233						453						578						672						1,250						442						486						928
Total Animal Health segment sales			459						1,012						1,472						342						759						1,101						896						1,994						2,890						726						1,588						2,314
Other segment sales (4)			—						—						—						—						—						—						—						—						—						23						—						23
Total segment sales			5,106						6,345						11,452						4,300						4,979						9,279						9,837						12,271						22,108						9,015						10,406						19,420
Other (5)			(6)						(44)						(50)						22						52						74						53						(132)						(79)						38						182						221
			$	5,100					$	6,301					$	11,402					$	4,322					$	5,031					$	9,353					$	9,890					$	12,139					$	22,029					$	9,053					$	10,588					$	19,641

U.S. plus international may not equal total due to rounding.

(1)    Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).

(2)    Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4).

(3)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.

(4)    Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested in the first quarter of 2020.

(5)    Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales.

Consolidated revenues by geographic area

Consolidated sales by geographic area where derived are as follows:

			Three Months Ended June 30,												Six Months Ended June 30,
($ in millions)			2021						2020						2021						2020
United States			$	5,100					$	4,322					$	9,890					$	9,053
Europe, Middle East and Africa			3,333						2,622						6,569						5,591
China			975						623						1,697						1,269
Japan			661						621						1,291						1,204
Asia Pacific (other than China and Japan)			594						489						1,168						1,015
Latin America			532						423						1,032						875
Other			207						253						382						634
			$	11,402					$	9,353					$	22,029					$	19,641

Reconciliation of segment profits to income before taxes

A reconciliation of segment profits to Income from Continuing Operations Before Taxes is as follows:

			Three Months Ended June 30,												Six Months Ended June 30,
($ in millions)			2021						2020						2021						2020
Segment profits:
Pharmaceutical segment			$	7,257					$	5,832					$	13,845					$	12,209
Animal Health segment			552						408						1,124						887
Other segment			—						—						—						2
Total segment profits			7,809						6,240						14,969						13,098
Other profits			(79)						43						(113)						163
Unallocated:
Interest income			9						14						20						39
Interest expense			(202)						(209)						(401)						(421)
Amortization			(357)						(599)						(871)						(988)
Depreciation			(332)						(367)						(673)						(733)
Research and development			(4,175)						(1,956)						(6,480)						(4,020)
Restructuring costs			(82)						(82)						(380)						(152)
Other unallocated, net			(874)						(343)						(1,367)						(1,284)
			$	1,717					$	2,741					$	4,704					$	5,702

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

+ Details

Name:	us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration